Brief: Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
07/04/2025 21:02
April 7 (Reuters) - Innocan Pharma Corp INNO.CD: INNOCAN PHARMA BROADENS INTELLECTUAL PROPERTY COVERAGE FOR ITS LIPOSOMAL CBD INJECTION ACROSS ASIA AND ANNOUNCES PRIVATE PLACEMENT OF UNITS Source text: ID:nCNWgKmsLa Further company coverage: INNO.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innocan Pharma
See all newsBrief: Innocan Pharma Corp To Offer Up To 3.75 Million Units In IPO - SEC Filing
Brief: Innocan Pharma Announces Promising Results Of LPT-CBD Administered To Gottingen Minipigs
Brief: Innocan Pharma Corp - Liposomal Cbd Injection Technology Patent Allowed In Japan
Brief: Innocan Pharma Corp Now Sees U.S IPO Of 1.1 Million Units - SEC Filing
Brief: Innocan Pharma Announces Details Of Proposed Share Consolidation